Sunitinib is an oral, small-molecule, and multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST) in 2006. Here, NTRK1 is linked to gastrointestinal stromal tumor.